Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Sponsor
The First Affiliated Hospital of Zhengzhou University
Study ID
NCT03193424
Phase
PHASE2
Status
Unknown

Conditions

  • Advanced Esophageal Squamous Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .

Study Details

Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.

Key Dates

Start date
Oct 31, 2016
Status verified
Jun 2017
Primary completion
Dec 30, 2018
Completion
Dec 30, 2019

Study Design

Enrollment
120 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib
  • Active Comparator: docetaxel

Primary Outcome Measure

Progression-free survival (PFS) [ Time Frame: 6 months ]

Central Contacts